Repligen Q2 revenue beats estimates on higher orders; raises outlook

Overview

• US bioprocessing technology firm's Q2 revenue rose 12%, beating analyst expectations

• Q2 adjusted EPS increased to $0.54, beating analyst consensus

• Company raised FY26 organic revenue growth and adjusted EPS guidance

Outlook

• Repligen raises FY26 organic revenue growth guidance to 10.5%-13.5%

• Company now sees FY26 adjusted EPS of $2.03-$2.09

• Repligen expects BioLife Solutions acquisition to be accretive to revenue growth and margin

Result Drivers

• ORDER MOMENTUM - Co said strong order momentum from Q1 continued into Q2, supporting revenue growth

• PORTFOLIO DIVERSIFICATION - Co attributed growth to strength and diversification of its product portfolio

• ACQUISITION AGREEMENT - Co said definitive agreement to acquire BioLife Solutions is expected to strengthen cell therapy business and be accretive to revenue growth and margins

Company press release: ID:nGNX9xwyz3

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies distribution peer group is "buy"

• Wall Street's median 12-month price target for Repligen Corp is $180.00, about 37.3% above its July 27 closing price of $131.06

• The stock recently traded at 56 times the next 12-month earnings vs. a P/E of 56 three months ago

Reuters Recommended Reads

• July 27 - AstraZeneca profit beat, bullish tone ease worries over drug pipeline

• July 27 - Argenx to buy Forte Biosciences for about $2.2 billion

• July 27 - Universal Health Services cuts 2026 forecast on Medicaid reimbursement uncertainty

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)